SCHEMBL5714749

SCHEMBL5714749

Cc1ccnc(Cc2ccc(OC(=O)N3CCN(CCc4cccnc4)CC3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LTA4H P09960 1/20 0.42
DRD2 P14416 4/20 0.41
DRD3 P35462 4/20 0.41
THRB P10828 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715177 0.95 SIGMAR1 (0.44) KDM4EALDH1A1LTA4HDRD2DRD3
SCHEMBL6101400 0.93 KDM4E (0.44) KDM4EALDH1A1DRD2DRD3THRB
SCHEMBL5713844 0.91 KDM4E (0.55) KDM4EALDH1A1LMNAPOLB
SCHEMBL5714136 0.90 SIGMAR1 (0.45) KDM4EALDH1A1DRD2THRBHRH2
SCHEMBL5714317 0.88 KDM4E (0.47) KDM4EALDH1A1LTA4HDRD2DRD3
SCHEMBL6101747 0.88 SIGMAR1 (0.47) KDM4EALDH1A1DRD2HRH2HRH1
SCHEMBL5714638 0.87 TP53 (0.48) KDM4EALDH1A1LTA4HDRD2THRB
SCHEMBL5715256 0.86 TP53 (0.54) KDM4EALDH1A1THRBTP53LMNA
SCHEMBL5715189 0.85 TP53 (0.43) THRBRXFP1TP53LMNAPOLB
SCHEMBL6103531 0.85 KDM4E (0.54) KDM4EALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL KDM4E 1090/4885ALDH1A1 1504/4885LTA4H 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.